Researchers find clues to a functional HIV cure

Image
ANI
Last Updated : Feb 08 2019 | 4:00 PM IST

A new study now has identified a measurable indicator that could prove instrumental in the fight against HIV.

George Mason University's Yuntao Wu, focused on cofilin, a key protein that regulates cells to mobilise and fight against infection.

In an HIV-infected patient, cofilin dysfunction is a key factor in helper T cell defects, according to the research recently published in the journal Science Advances.

Helper T cells augment the body's immune response by recognising the presence of a foreign antigen and then helping the immune system mount a response.

Wu said, "When you have an infection, you need to mobilise the T cells," adding, "In HIV infection, there is a profound depletion of helper T cells in lymphoid tissues, such as those in the gut."

Wu and his team found that patients with HIV have "significantly lower" levels of cofilin phosphorylation--which provides a control of cofilin's activity with the addition of a phosphate--than healthy patients. Cofilin is a key protein that helps cells generate the driving force for migration. Proper cofilin phosphorylation is needed for cells to move in and out of tissues.

Their findings suggest that a lasting immune control to HIV isn't likely to come from antiretroviral therapy alone because it is not sufficient to repair the cofilin damage caused by HIV and to restore normal T cell migration in and out of tissues.

However, the researchers found that by stimulating the T cells with additional therapeutics, such as the α4β7 integrin antibody, they could modulate the levels of cofilin activity needed to restore T cell mobility.

The remedy has shown lasting effects in immune control of simian immunodeficiency virus (SIV), the simian form of the AIDS virus, in a monkey trial, but it has not showed the same results in HIV-infected human patients.

"Now we have a marker, and at least one target that we can focus on to discover new therapies to repair the immune damages for a functional cure," Wu said.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 08 2019 | 3:35 PM IST

Next Story